Avid Bioservices Inc (CDMO)

[Threes]

Look like you missed everything.

Sorry you are not getting names of new clients. I am sure in this cut throat world that is a smart and prudent policy. Let me highlight the copy and paste from the CC. they have obviously expanded the customer base and continue to do so.

Steve Schwartz -- First Analyst -- Analyst

Yeah. Yeah. Understood. With respect to Halozyme, in FY '18, they were about 55% of your revenue stream and certainly the news today that they've come to you for additional development work and what have you in manufacturing. That's fantastic news. Where do you think they finish up FY '19 and even in FY '20, where do you think they stand relative to that 55% of FY '18?

Roger Lias -- President and CEO

Yeah. I think, probably, they will be reduced maybe the -- again we -- before the nice increase in forecast that we got, I would have given you a lower number, but for fiscal -- the coming fiscal year, maybe they'll achieve as much as 40% because of some growth in -- significant growth in forecast. But again, over time, we should see -- it's not a bad problem to have, but we should see continue -- continued reduction in the percentage contribution. But we were happy to take a significant kick up recently..
Even with increases in Halo rev projections they are expected to drop into the 40% range due to new business offsetting the increase.
In addition to that we are expanding into additional revenue streams. we now have 20% projecting up tp 33% rev's from regulation, compliance and planning.